SciVision Biotech Inc.

Taiwan Stock Exchange 1786.TW

SciVision Biotech Inc. Current Liabilities for the year ending December 31, 2023: USD 4.72 M

SciVision Biotech Inc. Current Liabilities is USD 4.72 M for the year ending December 31, 2023, a 13.04% change year over year. Current liabilities are obligations that are expected to be settled within one year, including accounts payable, short-term debt, and other current liabilities.

SciVision Biotech Inc. Current Liabilities for the year ending December 31, 2022 was USD 4.18 M, a -72.79% change year over year.
SciVision Biotech Inc. Current Liabilities for the year ending December 31, 2021 was USD 15.35 M, a 255.15% change year over year.
SciVision Biotech Inc. Current Liabilities for the year ending December 31, 2020 was USD 4.32 M, a -13.91% change year over year.
SciVision Biotech Inc. Current Liabilities for the year ending December 31, 2019 was USD 5.02 M, a -27.12% change year over year.

Key data

Date	Current Liabilities	Total Non-Current Liabilities	Shareholders' Equity	Long-Term Debt

Taiwan Stock Exchange: 1786.TW

SciVision Biotech Inc.

CEO	Tai Xian Han
IPO Date	March 12, 2013
Location	Taiwan
Headquarters	1, South 1st Road
Employees	64
Sector	Health Care
Industries Pharmaceuticals Chemicals & Advanced Materials Cosmetics

Description

SciVision Biotech Inc. manufactures and sells hyaluronic acid products in Taiwan. It offers synovial fluid supplements, facial dermal implants, absorbable adhesion barriers, and intravesical instillation products. The company was founded in 2001 and is based in Kaohsiung, Taiwan.

Key trends

Past 5 years